Article

Trametinib Receives European Approval for B-Raf-mutant Metastatic Melanoma

GSK has received marketing authorization from the European Commission for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

BRAF V600

The European Commission has given marketing authorization for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a mutation, GlaxoSmithKline announced.

MEK1

MEK2

BRAF

BRAF V600

Trametinib (Mekinist), a kinase inhibitor that targets / activation and kinase activity, has not demonstrated clinical activity in patients who have progressed on a prior inhibitor therapy. Before taking trametinib, patients must have confirmation of a mutation using a validated test.

BRAF

V600E

V600K

The European Commission’s decision was based on results from the randomized, open-label phase 3 METRIC study of 322 patients with -mutant melanoma (types and ) who were either treatment-naïve or have received one prior chemotherapy treatment in the metastatic setting.

P

According to study results, treatment with trametinib resulted in a statistically significant increase in PFS compared to chemotherapy (HR= 0.45; 95% CI: 0.33, 0.63, <0.0001), with a median PFS of 4.8 months for patients taking trametinib (95% CI: 4.3, 4.9) vs. 1.5 months for chemotherapy (95% CI: 1.4, 2.7).

Read the original report: http://bit.ly/1rEVeHA

Source: Healio

Related Videos
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo